Pharmacology Watch
RSSArticles
-
Sildenafil Improves Insulin Sensitivity
Chronic use of sildenafil (Revatio, Viagra) improves insulin sensitivity in prediabetics, according to a new study.
-
Group Calls for Generic Drug Use
The American College of Physicians recommends the use of generic medications when possible.
-
FDA Actions
FDA approves reversal agents, signs off on schizophrenia drug, warns of liver damage associated with hepatitis C treatment, green lights hyperkalemia treatment, and approves the first oncolytic virus for the treatment of melanoma.
-
Rethinking Calcium Supplementation
Increasing calcium intake from dietary sources or supplements produces small, non-progressive increases in bone mineral density, which are unlikely to make a clinically significant reduction in fracture.
-
FDA Actions
FDA strengthens warning about canagliflozin, approves cariprazine to treat schizophrenia and bipolar disorder, and green lights insulin degludec, a new long-acting insulin analog.
-
Spironolactone Effective Add-on for Resistant Hypertension Patients
Spironolactone was the most effective add-on drug for treatment of resistant hypertension, suggesting that sodium retention plays a role in this condition.
-
Study: Delay Shingles Vaccine to Age 60
The shingles vaccine does not represent a good value for patients at age 50 years, according to generally accepted standards.
-
CDC Issues New Guidelines for Pneumococcal Vaccines
The time interval between the two vaccines improves the immune response.
-
Diabetes Drug Reduces Heart Failure, Cardiovascular Death Risk
Patients with type 2 diabetes at high risk for cardiovascular disease who received empagliflozin had significantly lower rates of the composite cardiac vascular outcome and death from any cause.
-
FDA Actions
In this section: Drug to treat hypoactive sexual desire disorder in premenopausal women goes live; new drug available to prevent delayed phase chemotherapy-induced nausea and vomiting; DPP-4 inhibitors used to treat type 2 diabetes may cause severe and disabling joint pain; and evolocumab receives approval.